Tammy et al, Through trial and error you will find a correct dosage. Try 50 mg daily....25 each 2x daily....if no results up the dosage until it works for you. Remember, there has never been a death from marijuana or CBD use. You might want to try a tincture or rub with CBD and THC. You won't get the psych high from it. Helps my friend with PArkinsons tremors. She takes 50mg of tincture and uses the rub morning and night. It is a miracle for arthritis. Good luck
The most widespread claim for environmental friendliness of hemp is that it has the potential to save trees that otherwise would be harvested for production of lumber and pulp. Earlier, the limitations of hemp as a pulp substitute were examined. With respect to wood products, several factors appear to favor increased use of wood substitutes, especially agricultural fibers such as hemp. Deforestation, particularly the destruction of old growth forests, and the world’s decreasing supply of wild timber resources are today major ecological concerns. Agroforestry using tree species is one useful response, but nevertheless sacrifices wild lands and biodiversity, and is less preferable than sustainable wildland forestry. The use of agricultural residues (e.g. straw bales in house construction) is an especially environmentally friendly solution to sparing trees, but material limitations restrict use. Another chief advantage of several annual fiber crops over forestry crops is relative productivity, annual fiber crops sometimes producing of the order of four times as much per unit of land. Still another important advantage is the precise control over production quantities and schedule that is possible with annual crops. In many parts of the world, tree crops are simply not a viable alternative. “By the turn of the century 3 billion people may live in areas where wood is cut faster than it grows or where fuelwood is extremely scarce” (World Commission on Environment and Development 1987). “Since mid-century, lumber use has tripled, paper use has increased six-fold, and firewood use has soared as Third World populations have multiplied” (Brown et al. 1998). Insofar as hemp reduces the need to harvest trees for building materials or other products, its use as a wood substitute will tend to contribute to preserving biodiversity. Hemp may also enhance forestry management by responding to short-term fiber demand while trees reach their ideal maturation. In developing countries where fuelwood is becoming increasingly scarce and food security is a concern, the introduction of a dual-purpose crop such as hemp to meet food, shelter, and fuel needs may contribute significantly to preserving biodiversity.
While researchers are calling for more robust studies on the role of CBD on mood disorders, there is promising research that points to CBD’s role as an anxiolytic – which means it has anti-anxiety effects. Another study showed CBD to have antidepressant effects comparable to those of the prescription antidepressant Imipramine. We noted above that CBD increases levels of glutamate and serotonin – and it’s these same neurotransmitters that play a crucial role in mood regulation.
Cannabinoids, terpenoids, and other compounds are secreted by glandular trichomes that occur most abundantly on the floral calyxes and bracts of female plants.[41] As a drug it usually comes in the form of dried flower buds (marijuana), resin (hashish), or various extracts collectively known as hashish oil.[7] In the early 20th century, it became illegal in most of the world to cultivate or possess Cannabis for sale or personal use.
Smoking marijuana is hands down the most widely used method of consuming cannabis. It’s also the simplest: a rolling paper and some dried marijuana flower are all you need. Other, more technological methods of smoking marijuana may be rising in popularity. But for many people, the social experience of passing weed around with some friends is what cannabis is all about.
Karl W. Hillig, a graduate student in the laboratory of long-time Cannabis researcher Paul G. Mahlberg[77] at Indiana University, conducted a systematic investigation of genetic, morphological, and chemotaxonomic variation among 157 Cannabis accessions of known geographic origin, including fiber, drug, and feral populations. In 2004, Hillig and Mahlberg published a chemotaxonomic analysis of cannabinoid variation in their Cannabis germplasm collection. They used gas chromatography to determine cannabinoid content and to infer allele frequencies of the gene that controls CBD and THC production within the studied populations, and concluded that the patterns of cannabinoid variation support recognition of C. sativa and C. indica as separate species, but not C. ruderalis.[52] The authors assigned fiber/seed landraces and feral populations from Europe, Central Asia, and Turkey to C. sativa. Narrow-leaflet and wide-leaflet drug accessions, southern and eastern Asian hemp accessions, and feral Himalayan populations were assigned to C. indica. In 2005, Hillig published a genetic analysis of the same set of accessions (this paper was the first in the series, but was delayed in publication), and proposed a three-species classification, recognizing C. sativa, C. indica, and (tentatively) C. ruderalis.[55] In his doctoral dissertation published the same year, Hillig stated that principal components analysis of phenotypic (morphological) traits failed to differentiate the putative species, but that canonical variates analysis resulted in a high degree of discrimination of the putative species and infraspecific taxa.[78] Another paper in the series on chemotaxonomic variation in the terpenoid content of the essential oil of Cannabis revealed that several wide-leaflet drug strains in the collection had relatively high levels of certain sesquiterpene alcohols, including guaiol and isomers of eudesmol, that set them apart from the other putative taxa.[79] Hillig concluded that the patterns of genetic, morphological, and chemotaxonomic variation support recognition of C. sativa and C. indica as separate species. He also concluded there is little support to treat C. ruderalis as a separate species from C. sativa at this time, but more research on wild and weedy populations is needed because they were underrepresented in their collection.
Preclinical research suggests that emetic circuitry is tonically controlled by endocannabinoids. The antiemetic action of cannabinoids is believed to be mediated via interaction with the 5-hydroxytryptamine 3 (5-HT3) receptor. CB1 receptors and 5-HT3 receptors are colocalized on gamma-aminobutyric acid (GABA)-ergic neurons, where they have opposite effects on GABA release.[35] There also may be direct inhibition of 5-HT3 gated ion currents through non–CB1 receptor pathways. CB1 receptor antagonists have been shown to elicit emesis in the least shrew that is reversed by cannabinoid agonists.[36] The involvement of CB1 receptor in emesis prevention has been shown by the ability of CB1 antagonists to reverse the effects of THC and other synthetic cannabinoid CB1 agonists in suppressing vomiting caused by cisplatin in the house musk shrew and lithium chloride in the least shrew. In the latter model, CBD was also shown to be efficacious.[37,38]
Every crop grown and every variety may be inspected and sampled by a TDA plant inspector prior to harvest. The grower should contact TDA 30 days prior to harvest for inspection. The license holder is responsible for paying all fees associated with the sample. Each sample is $150. Please keep in mind that the way you set up your production method, may influence the number of samples required to represent the amount of material being produced. Growing multiple varieties will also increase the sampling cost.
Traditionally, hemp stalks would be water-retted first before the fibers were beaten off the inner hurd by hand, a process known as scutching. As mechanical technology evolved, separating the fiber from the core was accomplished by crushing rollers and brush rollers that would produce a nearly clean fiber. After the Marijuana Tax Act was implemented in 1938, the technology for separating the fibers from the core remained "frozen in time".

A rather thorough analysis of the scope of the illicit marijuana industry in Canada for 1998 is reported at www.rcmp-grc.gc.ca/html/drugsituation.htm#Marihuana and summarized in MacLeod (1999). At least 800 tonnes (t) of marijuana were grown in Canada in 1998, representing a harvest of 4.7 million flowering plants. More than 50% of the marijuana available in Canada is grown domestically. An average mature plant was estimated to produce 170 g of “marketable substance.” The value of the Canadian crop is uncertain, but has been estimated to be in the billions of dollars annually (Heading 1998; MacLeod 1999).
Several of the cannabinoids are reputed to have medicinal potential: THC for glaucoma, spasticity from spinal injury or multiple sclerosis, pain, inflammation, insomnia, and asthma; CBD for some psychological problems. The Netherlands firm HortaPharm developed strains of Cannabis rich in particular cannabinoids. The British firm G.W. Pharmaceuticals acquired proprietary access to these for medicinal purposes, and is developing medicinal marijuana. In the US, NIH (National Institute of Health) has a program of research into medicinal marijuana, and has supplied a handful of individuals for years with maintenance samples for medical usage. The American Drug Enforcement Administration is hostile to the medicinal use of Cannabis, and for decades research on medicinal properties of Cannabis in the US has been in an extremely inhospitable climate, except for projects and researchers concerned with curbing drug abuse. Synthetic preparations of THC—dronabinol (Marinol®) and nabilone (Cesamet®)—are permitted in some cases, but are expensive and widely considered to be less effective than simply smoking preparations of marijuana. Relatively little material needs to be cultivated for medicinal purposes (Small 1971), although security considerations considerably inflate costs. The potential as a “new crop” for medicinal cannabinoid uses is therefore limited. However, the added-value potential in the form of proprietary drug derivatives and drug-delivery systems is huge. The medicinal efficacy of Cannabis is extremely controversial, and regrettably is often confounded with the issue of balancing harm and liberty concerning the proscriptions against recreational use of marijuana. This paper is principally concerned with the industrial uses of Cannabis. In this context, the chief significance of medicinal Cannabis is that, like the issue of recreational use, it has made it very difficult to rationally consider the development of industrial hemp in North America for purposes that everyone should agree are not harmful.
The term kief refers to the sticky, bulbous crystalline formations on the tip of a gland called a “trichome.” Trichomes are external resin glands packed with the chemicals that give marijuana its flavors and smells, called “terpenes.” They also contain high concentrations of cannabinoids. These chemicals which interact with our body to produce marijuana’s signature effects.
Hemp, or industrial hemp (from Old English hænep),[1] typically found in the northern hemisphere, is a variety of the Cannabis sativa plant species that is grown specifically for the industrial uses of its derived products.[2] It is one of the fastest growing plants[3] and was one of the first plants to be spun into usable fiber 10,000 years ago.[4] It can be refined into a variety of commercial items including paper, textiles, clothing, biodegradable plastics, paint, insulation, biofuel, food, and animal feed.[5]